INNOVENT BIO (01801.HK) will hold a Board of Directors meeting on March 26 to approve the annual performance.
Glory Exchange reported on March 11 that INNOVENT BIO (01801.HK) announced that the Board of Directors will hold a meeting on March 26, 2025, to review and approve the annual performance of the company and its subsidiaries for the fiscal year ending December 31, 2024, and the proposed final dividend distribution (if any).
INNOVENT BIO: DATE OF BOARD MEETING
Express News | Innovent Is Said to Consider Licensing Partnership for Cancer Drug- Bloomberg News
National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two
① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.
The investment secrets in the government work report: Analyzing the collaborative logic of the Global Strategy and policies of Guoshengtang (2273.HK).
The report clearly states to strengthen basic Medical and health services.
[Brokerage Focus] HAITONG INT'L maintains INNOVENT BIO (01801) rating of "Outperform the Market", indicating that its future innovative research and development is expected to continue to deliver results.
Jinwu Financial News | HAITONG INT'L issued a Research Report indicating that INNOVENT BIO (01801) achieved revenue of 6.21 billion yuan in 2023, of which product revenue was 5.73 billion yuan, a year-on-year increase of 38.4%. The rapid growth in product revenue is mainly attributed to the priority positioning and rapid volume increase of PD-1; Other commercialized products also maintained good growth. As of February 2025, the company has commercialized 13 products, with 4 varieties under NMPA review (IGF-R, Marsduod Peptide, IL-23p19, CTLA-4, new indications for PD-1...), and 4 new drug molecules already have entered or will soon enter Phase III.
